Envoy Therapeutics, based in Jupiter, Florida, is a drug discovery company developing compounds that target motor circuitry compromised in Parkinson’s disease. The company uses its bacTRAP® technology to identify drug targets selectively expressed in brain circuits of therapeutic interest, aiming to minimize activity in circuits that may trigger unwanted side effects. Envoy’s current program focuses on modulation of a receptor target the company identified to achieve symptomatic benefit similar to dopamine replacement therapy. Its objective is to develop an oral therapeutic that provides sustained efficacy with minimal acute and long-term side effects. The company's drug discovery efforts are led by Steve Hitchcock, Ph.D., Senior Vice President of Drug Discovery. Financially, Envoy has received support from The Michael J. Fox Foundation, including a $1.2M second grant to advance its lead programs. Envoy Therapeutics is a Jupiter, Fla.-based new drug discovery company. It focuses on discovering and developing new treatments for neurological and psychiatric diseases. The company closed an $8M financing round consisting of a private placement of Series A Preferred Stock. The financing was led by 5AM Ventures, with participation from Takeda Research Investment and Roche Venture Fund. Envoy will use the proceeds to discover and develop new treatments and to build a portfolio of drugs. Co-founder and CEO Brad Margus said the funds are intended to demonstrate the power of the company's technology through select partnerships with global pharmaceutical companies and internal drug development.

Total raised

$9M

Funding rounds

2

Latest round

Grant

Latest activity

May 2012